ACE-1702

N/A

Report date: 2022/09/06 18:04:08

Base Information

Drug NameACE-1702
Drug Alias NameAnti-HER2 oNK cells (Acepodia)ACE-1702
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAcepodia Taiwan Subsidiary
China Registration ClassN/A

Develop Information

Active CompaniesAcepodia Biotech IncJw Therapeutics (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A